Pharmaceutical Development Corporation

Pharmaceutical Development Corporation (PDC) is a Taiwan-based biotechnology company and a subsidiary of Orient EuroPharma (OEP). Founded in 2008, the company specializes in the development of innovative botanical drugs for central nervous system (CNS) disorders. Its lead candidate, PDC-1421, is a botanical extract derived from Polygala tenuifolia being developed for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD). PDC-1421 has completed Phase 2 clinical trials, demonstrating potential as a non-stimulant alternative for ADHD with a favorable safety profile. The company leverages its expertise in botanical drug development and regulatory pathways to advance its pipeline toward commercialization.